QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Writing the Executive Summary in a PBRER

Test your understanding of the concepts covered by Writing the Executive Summary in a PBRER.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A completed signal evaluation found no change to the product's established safety profile and no regulatory or risk-management consequence. How should this generally be handled in the Executive Summary?

It should receive extensive discussion because every completed evaluation is equally important It should be omitted from the entire PBRER It should receive limited or no Executive Summary discussion unless it is relevant to the principal scientific messages It should be presented as evidence that the benefit-risk balance has improved

Question 2 of 10 A potential safety signal is under evaluation, but available evidence is limited and no conclusion about causality can yet be drawn. Which summary approach is most appropriate?

Describe it as a confirmed product risk Exclude it automatically because no final conclusion exists Describe its status and potential relevance using language that reflects the uncertainty State that the benefit-risk balance has changed solely because the signal exists

Question 3 of 10 A report contains extensive numerical analyses supporting a conclusion that the overall benefit-risk balance is unchanged. What is the most appropriate Executive Summary treatment?

Reproduce all analyses so the assessor does not need to consult the report State the relevant conclusion and its scientific implications, while leaving detailed numerical evidence in the appropriate sections Omit the conclusion because numerical data cannot be summarised reliably List every data source without explaining how it affects the benefit-risk balance

Question 4 of 10 Which statement best distinguishes a scientific synopsis from a shortened report template?

A scientific synopsis prioritises interpretation and implications rather than listing every section or activity A scientific synopsis excludes all discussion of regulatory actions A scientific synopsis contains only numerical findings and no conclusions A scientific synopsis is written independently of the detailed report

Question 5 of 10 Which of the following is generally least suitable for prominent inclusion in the Executive Summary?

A significant regulatory action affecting the product A conclusion from a post-authorisation safety study that changes understanding of a risk A routine operational activity with no material effect on scientific conclusions A new finding that may alter the overall benefit-risk balance

Question 6 of 10 Which practice is most likely to create inconsistency between the Executive Summary and the rest of the PBRER?

Drafting the summary after the integrated benefit-risk evaluation Rechecking the summary after changes to the conclusions and actions section Writing the summary before the detailed scientific assessment has been completed Using proportionate emphasis for findings with regulatory implications

Question 7 of 10 Which question is most useful when deciding whether a topic belongs in the Executive Summary?

Was the topic mentioned anywhere in the PBRER? Would removing the topic change the regulator's understanding of the overall benefit-risk assessment? Did the topic require the most staff time to prepare? Does the topic appear in the first half of the report?

Question 8 of 10 What is the most appropriate final quality review of an Executive Summary before report finalisation?

Check only spelling and formatting because scientific review occurred in the detailed sections Confirm that the summary remains consistent with the final integrated benefit-risk evaluation, conclusions and actions, and key supporting discussions Remove all uncertainty statements to make the summary more decisive Verify that the summary includes every topic appearing in the report

Question 9 of 10 Which situation illustrates imbalance in an Executive Summary?

Describing an emerging safety concern together with relevant benefit information and uncertainty Giving detailed attention to an isolated observation while barely mentioning a clinically important confirmed risk Explaining that a regulatory action was taken and linking it to the supporting evidence Giving greater emphasis to a finding that materially affects the benefit-risk balance

Question 10 of 10 Which wording best reflects appropriate treatment of uncertain evidence?

The data prove that the observed event is caused by the product The available findings suggest a possible association, although the evidence remains limited The event is definitively unrelated because causality has not been established The signal confirms a new risk requiring immediate regulatory action in all cases

Knowledge Assessment: Writing the Executive Summary in a PBRER

Cookie Settings